Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

157.92 -0.08 (-0.05%)
Official Closing Price Updated: 4:10 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
37 38 Next >
Where AbbVie Stands With Analysts
 
Via Benzinga
Credit Suisse Says AbbVie's Humira Patent Cliff Could Provide Momentum to Boost Growth
 
Via Benzinga
Analyst Ratings for AbbVie
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
What 8 Analyst Ratings Have To Say About AbbVie
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
What Does AbbVie's Debt Look Like?
Over the past three months, shares of AbbVie's Inc. (NYSE:ABBV) rose by 11.27%. Before having a look at the importance of debt, let's look at how much debt AbbVie's has. 
Via Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
AbbVie's Migraine Treatment Scores Canadian Approval
 
Via Benzinga
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Exicure Flags Bankruptcy Concerns, Shares Fall
 
Via Benzinga
2 Top Stocks to Buy in November and Hold Forever
Today is a great time to enter these long-term stories. 
Via The Motley Fool
This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy.
AbbVie's strong portfolio has what it takes to drive long-term growth. 
Via The Motley Fool
The Dividend Capture Strategy: What Investors Need To Know
This article will examine the dividend capture strategy, discuss the advantages and risks of the strategy, and provide a few examples of stocks that could be a good way for an investor to utilize this... 
Via Talk Markets
6 Dividend Growth Stocks
Want to know about dividend growth stocks that are increasing their dividends yet again? Today I want to tell you about six dividend growth stocks that just increased their dividends. 
Via Talk Markets
7 No-Brainer Dividend Stocks to Buy for 2023 and Beyond
With circumstances getting a tad too rough in the market, it’s time for investors to pivot toward no-brainer dividend stocks to buy. 
Via InvestorPlace
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
If You Like Dividends, You Should Love These 3 Stocks
These stocks are crushing the market this year and still have tremendous profit potential. 
Via The Motley Fool
3 Reasons to Buy AbbVie Stock Right Now
The drugmaker has something to offer to all kinds of investors. 
Via The Motley Fool
Why Dividend Investors Can Still Buy AbbVie Stock With No Worries
The big-pharma company's dividend remains safe and sound. 
Via The Motley Fool
The 7 Best Pharma Stocks to Buy Now
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks. 
Via InvestorPlace
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
These 3 Dividend ETFs Are a Retiree's Best Friend
This trio of exchange-traded funds has trounced the S&P 500 this year. 
Via The Motley Fool
Control Of Congress Up For Grabs In Midterms: 12 Stocks To Watch
As voters endeavor to select the congressional candidates they believe would best assist the U.S. in navigating through historical issues it is currently facing, investors are wondering what's going to... 
Via Benzinga
3 Dividend Kings Crushing The S&P 500 In 2022
Income investors love to target Dividend Aristocrats, companies that have increased their dividend payouts for a minimum of 25 consecutive years. 
Via Talk Markets
3 No-Brainer Dividend Stocks to Buy in November
There's no need for agonizing decision-making with these great dividend stocks. 
Via The Motley Fool
MarketBeat: Week in Review 10/31-11/4
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
2 Dividend Growth Stocks to Buy and Hold for Years
These companies have been raising their dividends by an average of more than 10% over the past five years. 
Via The Motley Fool
Better Buy: AbbVie vs. Walgreens Boots Alliance
Both these companies pay a dividend, but the similarities stop there. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.